Published in Eur Respir J on August 30, 2012
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2014) 1.73
Assessment and treatment of right ventricular failure. Nat Rev Cardiol (2013) 1.22
Pulmonary arterial hypertension. Orphanet J Rare Dis (2013) 1.18
Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. Br J Pharmacol (2015) 0.83
Pulmonary hypertension and right heart dysfunction in chronic lung disease. Biomed Res Int (2014) 0.82
Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. PLoS One (2015) 0.80
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. Biomed Res Int (2015) 0.78
New insights into the role of soluble guanylate cyclase in blood pressure regulation. Curr Opin Nephrol Hypertens (2014) 0.77
Treatment of pulmonary hypertension in interstitial lung disease: do not throw out the baby with the bath water. Eur Respir J (2013) 0.76
Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T (2014) 0.76
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Des Devel Ther (2017) 0.75
Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. Can Respir J (2017) 0.75
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to lung diseases and/or hypoxia. Ann Thorac Med (2014) 0.75
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.75
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Future Cardiol (2013) 0.75
Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis. Pulm Circ (2017) 0.75
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Inhaled iloprost for severe pulmonary hypertension. N Engl J Med (2002) 3.90
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation (2013) 3.90
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A (2007) 3.36
WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest (2009) 3.33
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation (2006) 2.67
Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med (2010) 1.94
Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med (2004) 1.84
Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J (2012) 1.83
Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol (2006) 1.76
Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. Circulation (2013) 1.62
Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol (2004) 1.58
Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol (2005) 1.57
Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost (2004) 1.53
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol (2012) 1.48
Dry powder aerosolization of a recombinant surfactant protein-C-based surfactant for inhalative treatment of the acutely inflamed lung. Crit Care Med (2010) 1.47
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol (2008) 1.43
Effects of a recombinant surfactant protein-C-based surfactant on lung function and the pulmonary surfactant system in a model of meconium aspiration syndrome. Crit Care Med (2006) 1.40
Evaluation of the -26G>A CC16 polymorphism in acute respiratory distress syndrome. Crit Care Med (2005) 1.40
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol (2013) 1.39
Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant (2005) 1.26
Microbial patterns signaling via Toll-like receptors 2 and 5 contribute to epithelial repair, growth and survival. PLoS One (2008) 1.22
Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest (2005) 1.19
Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest (2003) 1.15
The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis. Am J Respir Cell Mol Biol (2007) 1.15
N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest (2007) 1.14
Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J (2005) 1.13
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest (2005) 1.11
Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol (2010) 1.10
Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration (2011) 1.10
WNT/β-catenin signaling induces IL-1β expression by alveolar epithelial cells in pulmonary fibrosis. Am J Respir Cell Mol Biol (2013) 1.08
Potential applications of flat-panel volumetric CT in morphologic and functional small animal imaging. Neoplasia (2005) 1.06
Cell-specific nitric oxide synthase-isoenzyme expression and regulation in response to endotoxin in intact rat lungs. Lab Invest (2002) 1.06
Telomere length in circulating leukocytes is associated with lung function and disease. Eur Respir J (2013) 1.04
Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant (2009) 1.03
TGF-β directs trafficking of the epithelial sodium channel ENaC which has implications for ion and fluid transport in acute lung injury. Proc Natl Acad Sci U S A (2013) 1.01
miR-142-3p balances proliferation and differentiation of mesenchymal cells during lung development. Development (2014) 1.01
Acute lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty acids. Am J Respir Crit Care Med (2009) 1.01
Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation (2002) 1.00
Relatedness of medically important strains of Saccharomyces cerevisiae as revealed by phylogenetics and metabolomics. Yeast (2008) 1.00
Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest (2004) 0.98
Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med (2010) 0.98
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J (2012) 0.96
Legal Uncertainties. Dtsch Arztebl Int (2015) 0.96
Chronic thromboembolic pulmonary hypertension (CTEPH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol (2011) 0.96
The potential of biomarkers in pulmonary arterial hypertension. Am J Cardiol (2012) 0.96
Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol (2011) 0.95
Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Res Ther (2012) 0.93
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. Am J Respir Crit Care Med (2010) 0.93
Adult presentation of combined unilateral atresia of the right proximal pulmonary artery and left patent ductus arteriosus: case report and embryological considerations. Int J Cardiol (2009) 0.92
Hypoxia-inducible factor 2α plays a critical role in the formation of alveoli and surfactant. Am J Respir Cell Mol Biol (2012) 0.92
An ELISA technique for quantification of surfactant apoprotein (SP)-C in bronchoalveolar lavage fluid. Am J Respir Crit Care Med (2002) 0.91
Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation (2004) 0.91
Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung (2013) 0.90
Impairment of respiratory muscle function in pulmonary hypertension. Clin Sci (Lond) (2008) 0.90
Pivotal role of matrix metalloproteinase 13 in extracellular matrix turnover in idiopathic pulmonary fibrosis. PLoS One (2013) 0.90
Pulmonary surfactant in patients with Pneumocystis pneumonia and acquired immunodeficiency syndrome. Crit Care Med (2006) 0.89
Effect of inpatient rehabilitation on quality of life and exercise capacity in long-term lung transplant survivors: a prospective, randomized study. J Heart Lung Transplant (2011) 0.89
Contribution of the NADH-oxidase (Nox) to the aerobic life of Lactobacillus sanfranciscensis DSM20451T. Food Microbiol (2010) 0.89
Comparative proteome approach to characterize the high-pressure stress response of Lactobacillus sanfranciscensis DSM 20451(T). Proteomics (2006) 0.88
Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. Int J Cardiol (2011) 0.88
Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One (2012) 0.87
Pulmonary hypertension in chronic hypersensitivity pneumonitis. Lung (2012) 0.87
Changes in biochemical and biophysical surfactant properties with cardiopulmonary bypass in children. Crit Care Med (2003) 0.86
Alveolar derecruitment and collapse induration as crucial mechanisms in lung injury and fibrosis. Am J Respir Cell Mol Biol (2015) 0.86
Soluble polysialylated NCAM: a novel player of the innate immune system in the lung. Cell Mol Life Sci (2013) 0.86
Primary pulmonary hypertension in children may have a different genetic background than in adults. Pediatr Res (2004) 0.86
Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol (2012) 0.86
Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol (2007) 0.86
Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol (2008) 0.85
Comparison of genotypic and phenotypic cluster analyses of virulence determinants and possible role of CRISPR elements towards their incidence in Enterococcus faecalis and Enterococcus faecium. Syst Appl Microbiol (2011) 0.85
Changes in pulmonary surfactant function and composition in bleomycin-induced pneumonitis and fibrosis. Toxicol Appl Pharmacol (2004) 0.84
Standard PAH therapy improves long term survival in CTEPH patients. Clin Res Cardiol (2010) 0.84
Cardiopulmonary exercise testing to detect chronic thromboembolic pulmonary hypertension in patients with normal echocardiography. Respiration (2014) 0.84
Neurotrophic tyrosine kinase receptor B/neurotrophin 4 signaling axis is perturbed in clinical and experimental pulmonary fibrosis. Am J Respir Cell Mol Biol (2011) 0.83
Liver carboxylesterase cleaves surfactant protein (SP-) B and promotes surfactant subtype conversion. Biochem Biophys Res Commun (2006) 0.83
[Computed tomography of cystic lung diseases]. Rontgenpraxis (2004) 0.83
Ischemic and endotoxin pre-conditioning reduce lung reperfusion injury-induced surfactant alterations. J Heart Lung Transplant (2005) 0.83
Increase in alveolar antioxidant levels in hyperoxic and anoxic ventilated rabbit lungs during ischemia. Free Radic Biol Med (2004) 0.82
Optimization of experimental and modelling parameters for the differentiation of beverage spoiling yeasts by Matrix-Assisted-Laser-Desorption/Ionization-Time-of-Flight Mass Spectrometry (MALDI-TOF MS) in response to varying growth conditions. Food Microbiol (2013) 0.82
Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Res (2013) 0.82
Tidal volume in mechanical ventilation: the importance of considering predicted body weight. Am J Respir Crit Care Med (2008) 0.82
Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis. Transfus Med Hemother (2013) 0.82
Transcriptome analysis of Enterococcus faecalis toward its adaption to surviving in the mouse intestinal tract. Arch Microbiol (2014) 0.82
Spirometric reference values for advanced age from a South german population. Respiration (2012) 0.81
High blood pressure, antihypertensive medication and lung function in a general adult population. Respir Res (2011) 0.81
Optimization of Matrix-Assisted-Laser-Desorption-Ionization-Time-Of-Flight Mass Spectrometry for the identification of bacterial contaminants in beverages. J Microbiol Methods (2013) 0.81
Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis? Histol Histopathol (2013) 0.81